Amid global uncertainty, Bayer Pharma, led by Stefan Oelrich, pursues strategic transformation to boost resilience, drive innovation, and secure sustainable growth in a changing healthcare landscape.
Bayer and Kumquat Biosciences announced today that they have entered into an exclusive worldwide license and collaboration to develop and commercialize Kumquat's KRAS-G12D inhibitor.
Fluor Corporation announced today that it has completed construction of Bayer’s first global Cell Therapy Launch Facility in Berkeley, California. Completion was celebrated on October 10, 2023, at the new facility with local officials, dignitaries, Bayer employees, and clients.
Bayer’ Crop Science division plans to invest €220 million in a new research and development (R&D) facility at its Monheim, Germany site. This is the company’s largest single investment in its crop protection business in Germany since the founding of the Monheim campus in 1979, Bayer said.
After months of anticipation, the US Supreme Court has deflated Bayer’s hopes that the court’s conservative majority would vote to hear its appeal to overturn a $25 million appeals court verdict in favor of Edwin Hardeman.
Bayer has won its fourth consecutive appeal of a US court case previously decided in favor of a plaintiff who claimed that Monsanto’s glyphosate-based Roundup herbicide caused his non-Hodgkin lymphoma.